Cannabidiol

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid derived from Cannabis sativa that modulates the endocannabinoid system primarily through indirect antagonism of CB1 receptors and direct agonism of TRPV1 and serotonin 5-HT1A receptors. Its most rigorously demonstrated clinical application is reducing seizure frequency in treatment-resistant epilepsy syndromes such as Dravet and Lennox-Gastaut.

Origin & History

Cannabidiol (CBD) is a non-psychoactive phytocannabinoid extracted from Cannabis sativa L. (industrial hemp varieties containing <0.3% THC), primarily from the plant's inflorescences. Commercial CBD is produced through supercritical CO₂ extraction followed by winterization, chromatography, and crystallization to yield high-purity crystals (>99% CBD).

Historical & Cultural Context

Cannabis sativa has been used in Traditional Chinese Medicine (as 'mafen') and Ayurveda (as 'bhang') for over 2000 years to treat pain, inflammation, seizures, and anxiety. Historical texts like the Shennong Bencao Jing (100-200 AD) documented its use for 'wind-evil' disorders (epilepsy-like conditions) and rheumatism.

Health Benefits

• Reduces seizures in treatment-resistant epilepsy by 42.9% (Strong evidence from multiple phase 3 RCTs, PMID: 27624143)
• Decreases psychotic symptoms in schizophrenia (Moderate evidence from RCT showing PANSS score improvement, PMID: 20815812)
• Alleviates acute anxiety during stressful situations (Moderate evidence from small RCT, PMID: 21307846)
• Provides moderate chronic pain relief (Preliminary evidence from meta-analysis showing SMD -0.43, PMID: 34569679)
• May offer neuroprotective effects through AMPK/mTOR autophagy activation (Preliminary evidence from mechanistic studies, PMID: 30583700)

How It Works

CBD exerts its anticonvulsant and anxiolytic effects primarily by acting as a positive allosteric modulator of GABA-A receptors and an agonist at serotonin 5-HT1A receptors, reducing neuronal excitability and modulating fear-circuit signaling in the amygdala. Unlike THC, CBD has negligible affinity for CB1 and CB2 receptors but inhibits the reuptake and hydrolysis of the endogenous cannabinoid anandamide by blocking fatty acid amide hydrolase (FAAH), elevating anandamide tone. Additionally, CBD antagonizes GPR55 receptors and activates TRPV1 channels, contributing to its anti-inflammatory and nociceptive modulatory properties.

Scientific Research

Pivotal epilepsy trials include GWPCARE1 (n=214) showing 42.9% seizure reduction with 20mg/kg/day CBD (PMID: 27624143), and a 2020 meta-analysis of 8 RCTs (n=670) confirming significant seizure reduction (PMID: 32383718). Additional RCTs demonstrate efficacy in schizophrenia (n=88, PMID: 20815812) and social anxiety (n=11, PMID: 21307846), though evidence quality varies by condition.

Clinical Summary

The strongest evidence for CBD comes from three Phase 3 randomized controlled trials supporting FDA approval of Epidiolex (pharmaceutical-grade CBD) for Dravet syndrome and Lennox-Gastaut syndrome, where 20 mg/kg/day reduced median monthly convulsive seizures by 42.9% versus 17.2% for placebo (PMID: 27624143). A randomized, double-blind RCT in 88 patients with schizophrenia found adjunctive CBD (150–600 mg/day) significantly improved Positive and Negative Syndrome Scale (PANSS) scores compared to placebo (PMID: 20815812), though sample sizes remain modest and replication is needed. Acute anxiolytic effects have been demonstrated in simulated public speaking paradigms at single doses of 300 mg, but long-term RCT data for generalized anxiety disorder is limited. Overall, evidence is strong for epilepsy, moderate for psychosis, and preliminary for anxiety.

Nutritional Profile

Cannabidiol (CBD) is a pure phytocannabinoid compound (molecular formula C21H30O2, MW 314.46 g/mol), not a food ingredient with classical macronutrient or micronutrient content. As an isolated compound, it contains no protein, carbohydrates, fiber, or minerals. Key physicochemical and bioactive properties: CBD concentration in pharmaceutical-grade isolate is ≥98% purity (e.g., Epidiolex contains 100mg/mL CBD in sesame oil with ethanol and strawberry flavoring as excipients). In hemp-derived full-spectrum extracts, CBD typically ranges from 2–20% by dry weight depending on cultivar. Bioactive compound profile: CBD itself is the primary active molecule; full-spectrum preparations also contain minor cannabinoids (CBG ~0.1–1%, CBN trace amounts, CBDV trace), terpenes (myrcene, limonene, linalool at 0.1–0.5% collectively), and flavonoids (cannflavin A and B, apigenin at trace levels <0.1%). Fat content: CBD isolate is lipophilic (log P ≈ 6.3), requiring a lipid carrier for formulation; sesame oil-based formulations contain approximately 79% unsaturated fatty acids (oleic ~40%, linoleic ~38%). Bioavailability is highly route-dependent: oral bioavailability is low at 6–19% due to extensive first-pass hepatic metabolism (CYP3A4, CYP2C19); sublingual administration improves bioavailability marginally to ~12–35%; inhalation yields highest bioavailability at 31–56% with Tmax ~3–10 minutes; lipid co-administration increases oral absorption by approximately 3-fold (Cmax increases from ~0.8 ng/mL to ~2.5 ng/mL at 10mg/kg dose). Half-life is 18–32 hours with chronic dosing. Protein binding is >94% (primarily albumin and lipoproteins). No significant vitamin or mineral content in isolated form.

Preparation & Dosage

Epilepsy: 10-20 mg/kg/day divided twice daily (standardized oral solution). Schizophrenia: 600-1000 mg/day (oral capsules, ≥98% purity). Anxiety: 300-600 mg single dose. Pain: 25-175 mg/day (broad-spectrum extracts). Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Melatonin, L-theanine, Magnesium glycinate, Curcumin, Omega-3 fatty acids

Safety & Interactions

Common dose-dependent side effects of CBD include somnolence, diarrhea, decreased appetite, and transaminase elevations (hepatotoxicity risk increases notably above 20 mg/kg/day, particularly when co-administered with valproate). CBD is a potent inhibitor of CYP2C19 and CYP3A4 enzymes, meaning it can significantly raise plasma levels of clobazam, warfarin, and other substrates, necessitating therapeutic drug monitoring and potential dose adjustments. CBD should be used with caution in individuals taking CNS depressants due to additive sedation, and its use is contraindicated in those with known hypersensitivity to cannabinoids or sesame oil (present in Epidiolex formulation). Safety data in pregnancy and lactation is insufficient to establish safety; CBD crosses the placenta and is present in breast milk, so use should be avoided in these populations.